Topotecan and cyclophosphamide in adults with relapsed sarcoma

Area of Science:

• Medical Oncology
• Sarcoma Research
• Clinical Trials

Background:

• The combination of topotecan and cyclophosphamide (TC) has demonstrated activity in pediatric recurrent sarcoma, particularly Ewing's sarcoma (EWS).
• Limited data exists on the efficacy and toxicity of TC in adult patients with recurrent sarcoma.

Purpose of the Study:

• To evaluate the toxicity and response rates of the topotecan and cyclophosphamide (TC) combination in adult patients with recurrent sarcoma.

Main Methods:

• Retrospective review of adult patients treated with TC (topotecan 0.75 mg/m²/day, days 1-5; cyclophosphamide 250 mg/m²/day, days 1-5) every 21 days from 2005-2010.
• Analysis of patient demographics, sarcoma subtypes, treatment response, toxicity, and survival outcomes.

Main Results:

• Fifteen adult patients with various recurrent sarcomas (RMS, EWS, SS, LMS, DSRCT) were included.
• Median time to progression was 2.5 months; partial responses were observed in 2/6 RMS and 1/2 SS.
• Hematologic toxicities were common, with 47% requiring blood product transfusions and 33% experiencing fever/neutropenia.

Conclusions:

• The TC combination is tolerable in adults with recurrent sarcoma but demonstrates only modest anti-tumor activity.
• Alternative treatment strategies should be explored for this high-risk patient population.